Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening: Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

Study Overview

The purpose of this study is to determine the effectiveness of progesterone given by mouth for minimizing drug EKG response to a drug.

Study Description

Our objective is to evaluate and compare the efficacy of novel therapeutic approaches to reduce the risk of drug-induced QTc interval prolongation and TdP.

Additional Information

Participants will be paid for their participation.

  • IRB Number: 1806935117
  • Research Study Identifier: TX9173
  • Principal Investigator: James Tisdale

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.